Candid Therapeutics is continuing its mission to flesh out a pipeline of T-cell engagers in record time, signing a ...

AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...

Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...

CytomX Therapeutics is shrinking its headcount by 40% as the biotech regroups and looks at fresh ways to conserve cash.

Because of the risks biopsies can pose to patients, the FDA recommends only requiring them as part of trial participation if ...

When Michael Adams was researching health insurance options in 2023, he had one very specific requirement: coverage for ...

More than two years after acquiring Tarus Therapeutics, Portage Biotech is relaunching Tarus’ adenosine receptor antagonists ...

British tech firm Basecamp Research is making a big push forward to further its mission of developing programmable genetic ...

I-Mab has begun the new year with a pipeline pivot, pausing work on an asset that Sanofi bought into last year to focus on ...

Xeno Biosciences may have been unable to prove that its drug delivering oxygen to the gastrointestinal tract can induce ...

Oculis’ peptidomimetic small molecule has been shown to help protect the eyes of patients with inflammation of the optic ...

Overall, biopharma layoffs rose ever so slightly in 2024 compared to the year before, though the number of layoff rounds ...